In pre-clinical studies, CD73 has been shown to restrict the cytotoxic anti-tumor activity of CD8+ T cells84, while CD226, an adhesion molecule and activating receptor has been shown to be important for NK cell anti-tumor activity in vitro85 and in patients with cancer86. The gene discussed is CD8A; the disease is neoplasm.